LY4086940
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Eli Lilly · Phase 1 · Completed · Enrollment 219
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Part A: LY4086940 Single Dose (Healthy Participants) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part A: Placebo Single Dose (Healthy Participants) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part A: LY4086940 Multiple Dose (Healthy Participants) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part A: Placebo Multiple Dose (Healthy Participants) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part B: Placebo Multiple Dose (Participants with Overweight or Obesity) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Part E (Open-Label): LY4086940 Single Dose (Healthy Participants) | Obesity + T2D | n/r | n/r | n/r | n/r |